<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02532036</url>
  </required_header>
  <id_info>
    <org_study_id>TB040</org_study_id>
    <nct_id>NCT02532036</nct_id>
  </id_info>
  <brief_title>MVA85A Aerosol vs Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M. tb) Infection</brief_title>
  <official_title>A Phase I Trial to Compare the Safety and Immunogenicity of Candidate TB Vaccine MVA85A Administered by the Aerosol Inhaled Route and the Intramuscular Route in Healthy Adult Volunteers Who Are Latently Infected With Mycobacterium Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TB040 is a clinical trial to investigate and compare the effects of a candidate Tuberculosis&#xD;
      (TB) vaccine, MVA85A, administered by the aerosol inhaled route and the intramuscular route&#xD;
      in healthy adult volunteers who are latently infected with Mycobacterium tuberculosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor recruitment&#xD;
  </why_stopped>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">October 4, 2018</completion_date>
  <primary_completion_date type="Actual">October 4, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AE)</measure>
    <time_frame>Up to Day 168</time_frame>
    <description>Actively and passively collected data on adverse events via diary card for 14 days after vaccination and at each visit over 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Laboratory Markers of Immunity</measure>
    <time_frame>Up to Day 168</time_frame>
    <description>Evaluation of ex-vivo ELISpot and intracellular cytokine staining in blood and bronchoalveolar lavage (BAL) samples.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Starter Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive 1x10^7 pfu aerosol inhaled MVA85A at day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive 5x10^7 pfu aerosol inhaled MVA85A, and intramuscular saline placebo both at day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive 5x10^7 pfu intramuscular MVA85A, and aerosol inhaled saline placebo both at day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aerosol inhaled MVA85A</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Starter Group</arm_group_label>
    <other_name>MVA85A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intramuscular MVA85A</intervention_name>
    <arm_group_label>Group B</arm_group_label>
    <other_name>MVA85A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intramuscular Saline placebo</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aerosol inhaled Saline placebo</intervention_name>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Volunteers must meet all of the following criteria to enter the trial:&#xD;
&#xD;
          -  Healthy adult aged 18-55 years&#xD;
&#xD;
          -  Resident in or near Oxford, Birmingham or London for the duration of the trial period&#xD;
&#xD;
          -  Screening IGRA positive&#xD;
&#xD;
          -  Ineligible for chemoprophylaxis for latent M.tb infection, declined prophylaxis or&#xD;
             considered low risk due to distant contact history&#xD;
&#xD;
          -  Chest Computed Tomography (CT) normal; or abnormal with features consistent with&#xD;
             primary M.tb infection but no features suggestive of active disease&#xD;
&#xD;
          -  No relevant findings in medical history or on physical examination&#xD;
&#xD;
          -  Allow the Investigators to discuss the individual's medical history with their General&#xD;
             Practitioner&#xD;
&#xD;
          -  Use effective contraception for the duration of the trial period (females only)&#xD;
&#xD;
          -  Refrain from blood donation during the trial&#xD;
&#xD;
          -  Give written informed consent&#xD;
&#xD;
          -  Allow the Investigator to register volunteer details with a confidential database (The&#xD;
             Over-volunteering Protection Service) to prevent concurrent entry into clinical trials&#xD;
&#xD;
          -  Able and willing (in the Investigator's opinion) to comply with all the trial&#xD;
             requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Volunteers must meet none of the following criteria to enter the trial:&#xD;
&#xD;
          -  Participation in another research study involving receipt of an investigational&#xD;
             product in the 30 days preceding enrolment, or planned use during the trial period&#xD;
&#xD;
          -  Prior vaccination with candidate vaccine MVA85A, candidate vaccine FP85A,any other&#xD;
             recombinant MVA vaccine or any other candidate TB vaccine&#xD;
&#xD;
          -  Administration of immunoglobulins and/or any blood products within the three months&#xD;
             preceding the planned trial vaccination date&#xD;
&#xD;
          -  Clinically significant history of skin disorder, allergy, atopy, immunodeficiency&#xD;
             (including HIV), cancer (except BCC or CIS), cardiovascular disease, gastrointestinal&#xD;
             disease, liver disease, renal disease, endocrine disorder, neurological illness,&#xD;
             psychiatric disorder, drug or alcohol abuse&#xD;
&#xD;
          -  Concurrent oral or systemic steroid medication or the concurrent use of other&#xD;
             immunosuppressive agents&#xD;
&#xD;
          -  History of anaphylaxis to vaccination or any allergy likely to be exacerbated by any&#xD;
             component of the trial vaccine, sedative drugs, or any local or general anaesthetic&#xD;
             agents&#xD;
&#xD;
          -  Pregnancy, lactation or intention to become pregnant during trial period&#xD;
&#xD;
          -  Any respiratory disease, including asthma&#xD;
&#xD;
          -  Current smoker&#xD;
&#xD;
          -  Clinically significant abnormality on screening CT thorax&#xD;
&#xD;
          -  Clinically significant abnormality of pulmonary function tests&#xD;
&#xD;
          -  Any nasal, pharyngeal, or laryngeal finding which precludes bronchoscopy&#xD;
&#xD;
          -  Current use of any medication taken through the nasal or inhaled route including&#xD;
             cocaine or other recreational drugs&#xD;
&#xD;
          -  Clinical, radiological, or laboratory evidence of current active TB disease&#xD;
&#xD;
          -  Past treatment for TB disease&#xD;
&#xD;
          -  Any clinically significant abnormality of screening blood or urine tests&#xD;
&#xD;
          -  Positive HBsAg, HCV or HIV antibodies&#xD;
&#xD;
          -  Any other significant disease, disorder, or finding, which, in the opinion of the&#xD;
             Investigator, may either put the volunteer at risk, affect the volunteer's ability to&#xD;
             participate in the trial or impair interpretation of the trial data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen McShane</last_name>
    <role>Study Director</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Moss</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Lipman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Free Hostpital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felicity Perrin</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College Hospital NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Warin Ward, Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIHR Wellcome Trust Clinical Research Facility, University of Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIHR/Wellcome Trust King's Clinical Research Facility</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>August 18, 2015</study_first_submitted>
  <study_first_submitted_qc>August 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2015</study_first_posted>
  <results_first_submitted>August 14, 2020</results_first_submitted>
  <results_first_submitted_qc>August 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 31, 2020</results_first_posted>
  <last_update_submitted>August 14, 2020</last_update_submitted>
  <last_update_submitted_qc>August 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MVA85A</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Aerosol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 19, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT02532036/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Starter Group</title>
          <description>Receive 1x10^7 pfu aerosol inhaled MVA85A at day 0.</description>
        </group>
        <group group_id="P2">
          <title>Group A</title>
          <description>Receive 5x10^7 pfu aerosol inhaled MVA85A</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Starter Group</title>
          <description>Received 1x10^7 pfu aerosol inhaled MVA85A at day 0.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events (AE)</title>
        <description>Actively and passively collected data on adverse events via diary card for 14 days after vaccination and at each visit over 6 months.</description>
        <time_frame>Up to Day 168</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Starter Group</title>
            <description>Receive 1x10^7 pfu aerosol inhaled MVA85.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events (AE)</title>
          <description>Actively and passively collected data on adverse events via diary card for 14 days after vaccination and at each visit over 6 months.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Markers of Immunity</title>
        <description>Evaluation of ex-vivo ELISpot and intracellular cytokine staining in blood and bronchoalveolar lavage (BAL) samples.</description>
        <time_frame>Up to Day 168</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All AEs occurring for 6 months following the vaccination that were observed by the investigator or reported by the volunteer, whether or not attributed to study medication, were recorded by volunteers on electronic diary cards or by staff on CRFs.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Starter Group</title>
          <description>Received 1x10^7 pfu aerosol inhaled MVA85A at day 0.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>radiological changes</sub_title>
                <description>transient asymptomatic radiological changes to the lung on CT scan at Day 28.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to significant challenges with recruitment at all UK sites this study has been terminated early.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Professor Helen McShane</name_or_title>
      <organization>University of Oxford</organization>
      <phone>+44 (0)1865 617606</phone>
      <email>helen.mcshane@ndm.ox.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

